Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIT101 vs Rituximab in Low Tumor Burden Follicular Lymphoma
NCT02809053Phase 3Completed
- Sponsor
- Archigen Biotech Limited
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), sponsored by Archigen Biotech Limited. Started Jan 2017; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02809053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809053.